At BioCrea we turn concepts into drug candidates, creating first-in-class drugs to treat debilitating central nervous system (CNS) diseases. Through the combination of our unique discovery platforms, the use of patient-derived models and clinical data together with an experienced, visionary team, the company discovers and develops new drug candidates for pharmaceutical and biotechnology partners.
November 18, 2014
BioCrea invited to present NMDA NR2B NAM program at the Therapeutic Area Partnerships meeting on November 19-21, 2014 in Boston
September 23, 2014
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that Chief Executive Officer, Dr. Tom Kronbach, will present at three international life sciences conferences over the coming months.
June 30, 2014
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, announced today that it has received the “Top 100” award for 2014, which confirms BioCrea as one of the most innovative SMEs in Germany. This is the second time BioCrea has been listed among the “Top 100” most outstanding drivers of innovation in the country.